Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT

帕洛诺塞隆 医学 恶心 呕吐 消炎药 地塞米松 临床终点 化疗 随机对照试验 胃肠病学 麻醉 内科学 止吐药
作者
Huaqiang Zhou,Yuanyuan Zhao,Mingjun Zhang,Jun Yao,Shuang Leng,Xiu-Min Li,Lin Li,J Chen,Songnan Zhang,Xia Qin,Zhiquan Qin,Tienan Yi,Ruoyu Wang,Xiang Li,Yan Yu,Zhenghua Wang,Qinhong Zheng,Jiazhuan Mei,Aimin Zang,Na Li
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (9): 1123-1136 被引量:10
标识
DOI:10.1200/jco-24-01308
摘要

PURPOSE Mixed formulation of fosrolapitant and palonosetron (PALO), HR20013, is a novel fixed-dose intravenous antiemetic combination that could simultaneously antagonize neurokinin-1 and 5-hydroxytryptamine-3 receptors. This study was designed to evaluate the efficacy and safety of HR20013 plus dexamethasone (DEX) versus fosaprepitant (FAPR) plus PALO + DEX for preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). METHODS This is a noninferiority study. Chemotherapy-naïve patients were randomly assigned 1:1 to receive HR20013 (day 1) or FAPR + PALO (day 1) before each cycle of cisplatin-based HEC (two cycles in total), together with oral DEX (day 1-4). The primary end point was overall (0-120 hours) complete response (CR; no vomiting/no rescue therapy) rate in cycle 1. The key secondary end point was CR rate at the beyond delayed phase (120-168 hours) in cycle 1. RESULTS Three hundred seventy-three patients were enrolled to receive HR20013 + DEX and 377 to FAPR + PALO + DEX. The overall CR rate in cycle 1 was 77.7% for HR20013 + DEX and 78.2% for FAPR + PALO + DEX (difference = –0.9% [95% CI, –6.7 to 5.0]; one-sided P < .01), demonstrating that HR20013 + DEX was noninferior to FAPR + PALO + DEX. The superiority of HR20013 + DEX over FAPR + PALO + DEX in CR rate at the beyond delayed phase in cycle 1 was not met (90.3% v 86.5%; two-sided P = .11). In cycle 2, HR20013 + DEX showed greater proportions of patients reporting no impact on daily life at the delayed (24-120 hours) and beyond delayed phases compared with FAPR + PALO + DEX. The incidences of treatment-related adverse events were 35.7% during cycle 1 and 42.1% during entire study for HR20013 + DEX, versus 38.2% and 44.0% for FAPR + PALO + DEX. CONCLUSION HR20013 + DEX was noninferior to FAPR + PALO + DEX for preventing HEC-CINV and well tolerated, with the potential to reduce the impact of CINV on daily life.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
hyyy发布了新的文献求助10
1秒前
如小美发布了新的文献求助10
1秒前
1秒前
十七岁男高中生完成签到,获得积分10
1秒前
2秒前
ding的应助被yanifang采纳,获得10
3秒前
206拧绳哥完成签到,获得积分10
3秒前
4秒前
infinite发布了新的文献求助10
4秒前
51515发布了新的文献求助10
5秒前
206拧绳哥发布了新的文献求助10
6秒前
6秒前
机灵柚子的应助被雪儿采纳,获得10
6秒前
7秒前
舒适采梦发布了新的文献求助10
8秒前
杨洋完成签到 ,获得积分10
8秒前
8秒前
李健的应助被mask采纳,获得10
8秒前
乐乐的应助被菜鸟采纳,获得10
8秒前
8秒前
ddd完成签到,获得积分10
8秒前
223老师完成签到,获得积分10
8秒前
桐桐发布了新的文献求助10
9秒前
Zxz完成签到,获得积分10
9秒前
mr完成签到 ,获得积分10
9秒前
lq发布了新的文献求助10
10秒前
10秒前
易木发布了新的文献求助10
11秒前
丘比特的应助被瀛洲晚风采纳,获得30
12秒前
包容的墨镜关注了科研通微信公众号
13秒前
Jing发布了新的文献求助10
13秒前
英姑的应助被gfhdf采纳,获得10
15秒前
爆米花的应助被gfhdf采纳,获得10
15秒前
传奇3的应助被gfhdf采纳,获得10
15秒前
15秒前
科研通AI6.2的应助被gfhdf采纳,获得10
15秒前
英俊的铭的应助被gfhdf采纳,获得10
15秒前
打打的应助被gfhdf采纳,获得10
16秒前
丘比特的应助被gfhdf采纳,获得10
16秒前
大个的应助被gfhdf采纳,获得10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593